Paradigm Biopharmaceuticals Limited (ASX: PAR) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Paradigm Biopharmaceuticals Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Paradigm Biopharmaceuticals Limited (ASX: PAR)
Latest News
Share Fallers
Why Energy Resources, Paradigm, Piedmont Lithum, and Seek shares are dropping today
Share Gainers
Why Appen, Core Lithium, Paradigm, and Sayona Mining shares are racing higher
Share Fallers
Why Best & Less, Cettire, Life360, and Paradigm shares are sinking today
Healthcare Shares
Why is this ASX All Ords biotech share crashing 12% today?
Share Market News
Why Appen, GQG, Paradigm, and Talga shares are tumbling lower
Share Gainers
Boom! Guess which ASX All Ords share has surged 50% this week
Share Gainers
Why Allkem, Evolution, Paradigm, and Sayona Mining shares are zooming higher
Healthcare Shares
Why is the Paradigm share price rocketing 19% today?
Share Gainers
3 ASX All Ords shares that marched higher on Friday
Share Fallers
Why Beach, Bendigo and Adelaide Bank, Opthea, and Paradigm shares are sinking
Capital Raising
Paradigm Biopharmaceuticals share price freefalls 27% following $66m cap raise
Capital Raising
Up 90% in 2 weeks, here's why the Paradigm share price has been halted
Frequently Asked Questions
-
No, Paradigm does not pay shareholder dividends at this time.
-
Paradigm Biopharmaceuticals Limited listed on the ASX on 19 August 2015.
PAR ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Paradigm Biopharmaceuticals Limited
Paradigm Biopharmaceuticals Ltd (ASX: PAR) is a late-stage drug development company researching drug repurposing. The company seeks to identify and transform existing molecules to develop effective treatments for conditions with limited treatment options. Currently, more than 30% of therapies approved or launched globally represent drugs approved for new indications, reformulations, or new combinations of existing drugs.
Paradigm's current commercial prospect is injectable pentosan polysulfate sodium (PPS, or brand name Zilosul®) in the treatment of osteoarthritis. PPS is FDA-approved and has a track record of treating inflammation including bladder condition cystitis and is used in the EU for preventing deep vein thrombosis. Paradigm has advanced to Phase 3 trial stage investigating PPS for osteoarthritis treatment. The company is based in Melbourne with offices in the US and Europe.
